Neurocrine Biosciences Unveils Compelling Data on INGREZZA for Tardive Dyskinesia Treatment

New Insights on the Effectiveness of INGREZZA for Tardive Dyskinesia

Neurocrine Biosciences, Inc. has just released promising data regarding its medication INGREZZA® (valbenazine) in treating tardive dyskinesia (TD), a condition characterized by involuntary, repetitive movements. The new analysis from the KINECT® 4 clinical study highlights that 94% of adult participants achieved either symptomatic remission or notable symptomatic improvement after 48 weeks of treatment.

Key Findings from the KINECT 4 Study

The KINECT 4 study previously shared impressive results, stating that 59% of the participants had reached symptomatic remission—defined as scoring either zero or one across all assessed body regions on the Abnormal Involuntary Movement Scale (AIMS). Particularly, among those with moderate to severe TD, significant improvements were noted. It was reported that 63% of those with moderate TD and 54% of severe TD patients reached this stringent threshold. The recent post-hoc analysis dives deeper, revealing that even among those not meeting the strict criteria for symptomatic remission, many still saw substantial benefits. Specifically, 86% of those who didn’t achieve remission noted a ≥30% reduction in their AIMS score, with 67% registering a ≥50% reduction.

Statements from Neurocrine Biosciences

“This new analysis elucidates that treatment goals in tardive dyskinesia extend beyond mere remission thresholds,” stated Dr. Sanjay Keswani, Chief Medical Officer at Neurocrine Biosciences. Given that approximately 94% of patients receiving INGREZZA for 48 weeks reported symptomatic relief or meaningful improvements in their involuntary movements, this reinforces the wide clinical applicability of the drug in addressing TD symptoms.

Research on Hepatic Risk Factors

Additionally, a separate claims analysis examined over 176,000 patients recently diagnosed with TD, uncovering that a staggering 90% had at least one hepatic risk factor. This included conditions such as type 2 diabetes, hypertension, and substance abuse, which can lead to chronic liver disease. This finding underscores the critical need to assess hepatic risk factors in crafting personalized treatment plans for TD, especially since symptoms of liver dysfunction can often go unnoticed.

Clinical Implications

In summary, these revelations embark upon a larger dialogue regarding the ingrained complexities of managing tardive dyskinesia in broader patient demographics. INGREZZA stands as the lone VMAT2 inhibitor validated for patients with coexisting hepatic impairment, reflecting its unique capacity to cater to those in need of specific treatment accommodations. The newly presented data solidifies INGREZZA's role as not just a treatment option but a substantial ally in managing TD's often debilitating symptoms.

Future Directions

As Neurocrine Biosciences continues its mission to improve the lives of those affected by challenging neurological disorders, ongoing research and discussions about INGREZZA will pave the way for innovative treatments and better healthcare outcomes. The results and insights shared at the recent 2026 Psych Congress Elevate showcase an invigorated commitment to fully understanding and addressing tardive dyskinesia.

For further information about INGREZZA and its applications in treating tardive dyskinesia, please visit Neurocrine Biosciences' official webpage or consult with healthcare professionals specializing in neurological disorders.